Evaluation Of tuberculin skin test and booster effect in hemodialysis patients

Authors

Masomeh Alimagham1,*, Saied Aminiafshar1, Latif Gachkar1, Kamran Sharafim1, Mohammad Farahbakhsh1
1Infectious Diseases and Tropical Medicine Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, IR Iran
*Corresponding Author: Infectious Diseases and Tropical Medicine Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, IR Iran, Email: [email protected]

Archives of Clinical Infectious Diseases:Vol. 1, issue 1
Published online:Jan 31, 2006
Article type:Research Article
How to Cite:Alimagham M, Aminiafshar S, Gachkar L, Sharafim K, Farahbakhsh M. Evaluation Of tuberculin skin test and booster effect in hemodialysis patients. Arch Clin Infect Dis. 2006;1(1):. doi:

Abstract

Background:

Tuberculosis is an endemic disease in Iran which may occur more frequently among hemodialysis patients. We have evaluated tuberculin skin test (TST) in hemodialysis patients in a university hospital in 2003-2004.

Sixty-seven hemodialyis patients were enrolled for tuberculin skin tests. Indurations were measured 48-72 hours after the injection and then on the 7th day. Those with indurations less than 5mm in TST1 were introduced for TST2.

Results:

Of 67 patients, 18(26.9%) had indurations of less than 5mm in TST1 and were introduce for TST2 among whom 7 (39%) had an induration measured less than 5mm. Of 18 cases, 11 (61%) were revealed to have booster effect that represent a ratio of 16% of all studied hemodialysis patients in our study.

Conclusion:

It seems that the second TST is a better indicator of infectivity in hemodialysis patients, especially for patients who require repeated or annual estimation for M. tuberculosis infection.

Full Text

Full text is available in PDF

Copyright

© 2006, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

31
Jan
2006

Tetanus antitoxin levels and cutaneous anergy in hemodialysis patients in two university hospitals in Iran

Zohreh Aminzadeh,
Farhad Yaghmaei,
Aydin Poorkazemi,
Latif Gachkar

Aminzadeh Z, Yaghmaei F, Poorkazemi A, Gachkar L. Tetanus antitoxin levels and cutaneous anergy in hemodialysis patients in two university hospitals in Iran. Arch Clin Infect Dis. 2006;1(1):. doi:

31
Mar
2007

Evaluation of the results of thyroid function tests in hemodialysis patients

M R Sarookhani

Sarookhani MR. Evaluation of the results of thyroid function tests in hemodialysis patients. J Inflamm Dis. 2024;10(4):e155264. doi:

31
Mar
2007

Source and Response of Antibody to Hepatitis B Vaccine in Hemodialysis Patients

Zohreh Aminzadeh,
Hossein Akhavan,
Latif Gachkar

Aminzadeh Z, Akhavan H, Gachkar L. Source and Response of Antibody to Hepatitis B Vaccine in Hemodialysis Patients. Hepat Mon. 2007;7(1):. doi:

30
Sep
2009

Hepatitis B Infection in Hemodialysis Patients in Tehran Province, Iran

Mirta Mahdavimazdeh,
Seyed Mohammadmehdi Hosseini Moghaddam,
Seyed Moayed Alavian,
Hooman Yahyazadeh

Mahdavimazdeh M, Hosseini Moghaddam S, Alavian S, Yahyazadeh H. Hepatitis B Infection in Hemodialysis Patients in Tehran Province, Iran. Hepat Mon. 2009;9(3):. doi:

10
Sep
2013

Study the Anti-Toxoplasma Antibodies (IgG and IgM) in Hemodialysis Patients of Abadan and Khoramshahr Cities Southwest Iran in 2011 using ELISA

Sharif Maraghi,
Mohammad Jafar Yadyad,
Marjan Sheikhi,
Fatemeh Shamakhteh,
Seyed Mahmood Latifi

Maraghi S, Yadyad MJ, Sheikhi M, Shamakhteh F, Latifi SM. Study the Anti-Toxoplasma Antibodies (IgG and IgM) in Hemodialysis Patients of Abadan and Khoramshahr Cities Southwest Iran in 2011 using ELISA. Jundishapur J Microbiol. 2013;6(7):e7113. doi: https://doi.org/10.5812/jjm.7113

More by these authors

Masomeh AlimaghamPubMedScholar
Saied AminiafsharPubMedScholar
Latif GachkarPubMedScholar
Kamran SharafimPubMedScholar
Mohammad FarahbakhshPubMedScholar
Share
Cited by
Metrics